Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing

被引：0
|
作者：
Laurent Kodjikian
Lluís Arias Barquet
András Papp
Peter J. Kertes
Edoardo Midena
Jan Ernest
Rufino Silva
Thomas Schmelter
Tobias Niesen
Sergio Leal
机构：
[1] Croix-Rousse Teaching Hospital,Department of Ophthalmology
[2] Hospices Civils de Lyon,UMR
[3] Université Claude Bernard Lyon 1,CNRS 5510 Matéis, Villeurbanne
[4] University of Lyon,Department of Ophthalmology
[5] Hospital Universitario de Bellvitge,Department of Ophthalmology
[6] University of Barcelona,Department of Ophthalmology
[7] Semmelweis University,Department of Ophthalmology and Vision Sciences
[8] The John and Liz Tory Eye Centre,Department of Ophthalmology
[9] Sunnybrook Health Sciences Centre,Coimbra Institute for Clinical and Biomedical Research Faculty of Medicine (iCBR
[10] University of Toronto,FMUC)
[11] University Hospital,Ophthalmology Department
[12] Axon Clinical Research Center,undefined
[13] University of Coimbra,undefined
[14] Centro Hospitalar e Universitário de Coimbra (CHUC),undefined
[15] Association for Innovation and Biomedical Research on Light and Image (AIBILI),undefined
[16] Clinical Academic Center of Coimbra (CACC),undefined
[17] Bayer AG,undefined
[18] Bayer Consumer Care AG,undefined
来源：
Advances in Therapy | 2024年 / 41卷
关键词：
Anatomic outcomes; Anti-vascular endothelial growth factor; Fixed dosing; Functional outcomes; Intravitreal aflibercept; Neovascular age-related macular degeneration; Treat-and-extend; Treatment burden; Treatment interval;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1010 / 1024
页数：14
相关论文
共 50 条
  • [31] TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Barthelmes, Daniel
    Vuong Nguyen
    Daien, Vincent
    Campain, Anna
    Walton, Richard
    Guymer, Robyn
    Morlet, Nigel
    Hunyor, Alex P.
    Essex, Rohan W.
    Arnold, Jennifer J.
    Gillies, Mark C.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (01): : 20 - 28
  • [32] Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration
    Alaa Din Abdin
    Shady Suffo
    Fatima Asi
    Achim Langenbucher
    Berthold Seitz
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257 : 1671 - 1677
  • [33] A modified treat-and-extend regimen of aflibercept for treatment-na⟨ve patients with neovascular age-related macular degeneration
    Ohnaka, Masayuki
    Nagai, Yoshimi
    Sho, Kenichiro
    Miki, Katsuaki
    Kimura, Motoki
    Chihara, Tomoyuki
    Takahashi, Kanji
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (04) : 657 - 664
  • [34] Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration
    Abdin, Alaa Din
    Suffo, Shady
    Asi, Fatima
    Langenbucher, Achim
    Seitz, Berthold
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 257 (08) : 1671 - 1677
  • [35] Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis
    Nichani, Prem A. H.
    Popovic, Marko M.
    Dhoot, Arjan S.
    Pathak, Ananya
    Muni, Rajeev H.
    Kertes, Peter J.
    EYE, 2023, 37 (14) : 2855 - 2863
  • [36] Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis
    Prem A. H. Nichani
    Marko M. Popovic
    Arjan S. Dhoot
    Ananya Pathak
    Rajeev H. Muni
    Peter J. Kertes
    Eye, 2023, 37 : 2855 - 2863
  • [37] A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration
    Masayuki Ohnaka
    Yoshimi Nagai
    Kenichiro Sho
    Katsuaki Miki
    Motoki Kimura
    Tomoyuki Chihara
    Kanji Takahashi
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 657 - 664
  • [38] Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'
    Homer, N.
    Grewal, D. S.
    Mirza, R. G.
    Lyon, A. T.
    Gill, M. K.
    EYE, 2015, 29 (12) : 1630 - 1631
  • [39] Response to: ‘Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’
    N Homer
    D S Grewal
    R G Mirza
    A T Lyon
    M K Gill
    Eye, 2015, 29 : 1630 - 1631
  • [40] Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial
    Gillies, Mark C.
    Hunyor, Alex P.
    Arnold, Jennifer J.
    Guymer, Robyn H.
    Wolf, Sebastian
    Ng, Paul
    Pecheur, Francois L.
    McAllister, Ian L.
    JAMA OPHTHALMOLOGY, 2019, 137 (04) : 372 - 379
12345